Alto Neuroscience, Inc.
ANRO
$34.38
-$1.43-3.99%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -84.24M | -74.31M | -63.24M | -62.26M | -64.86M |
| Total Depreciation and Amortization | 689.00K | 674.00K | 661.00K | 674.00K | 632.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.62M | 11.03M | 10.78M | 10.28M | 9.62M |
| Change in Net Operating Assets | 2.65M | 299.00K | 33.00K | -1.97M | -479.00K |
| Cash from Operations | -68.29M | -62.30M | -51.77M | -53.27M | -55.08M |
| Capital Expenditure | -556.00K | -556.00K | -24.00K | -530.00K | -1.54M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -556.00K | -556.00K | -24.00K | -530.00K | -1.54M |
| Total Debt Issued | 0.00 | 750.00K | 20.44M | 20.44M | 21.69M |
| Total Debt Repaid | 0.00 | 0.00 | -10.21M | -10.21M | -10.21M |
| Issuance of Common Stock | 170.59M | 170.51M | 50.70M | 400.00K | 314.00K |
| Repurchase of Common Stock | -190.00K | -190.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.39M | -5.18M | -850.00K | -683.00K | -683.00K |
| Cash from Financing | 165.01M | 165.89M | 60.08M | 9.94M | 11.11M |
| Foreign Exchange rate Adjustments | -17.00K | -24.00K | -30.00K | -23.00K | -26.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.15M | 103.01M | 8.26M | -43.89M | -45.54M |